Nucleate Podcast Building Biotech: From the Lab to the Boardroom | Raj Devraj, CEO of Rectify Pharma
10 snips
May 14, 2025 Raj Devraj, CEO of Rectify Pharmaceuticals and a seasoned venture partner, shares his insights on the ever-evolving biotech landscape. He reflects on his journey from India to pharmaceutical success, emphasizing the need for determination and aggressive advancement. The conversation dives into the challenges of securing funding in a risk-averse market and the importance of strategic team-building. Raj also discusses the pivot to hepatobiliary diseases, advocating for innovative, broad applications of biotechnology while stressing mentorship and solid planning for aspiring entrepreneurs.
AI Snips
Chapters
Transcript
Episode notes
Growing up Hustling in India
- Raj Devraj describes India as a land of hustlers that taught him to be aggressive and stand out to advance himself.
- His experience shaped his career approach of hustle and determination from an early age.
Advice to PhD Trainees on Industry Transition
- PhD trainees should align goals early and be patient, as industry transitions and funding take longer than expected.
- Commitment and passion for science are critical despite low pay and a long slog.
Capital Efficiency in Tough Markets
- Current biotech funding demands ruthless capital efficiency and prioritizing pivotal experiments.
- Stretching funding as long as possible with strong product theses optimizes success in risk-averse markets.